Grown Rogue Details $15M New York Entry Financing and PharmaCann Acquisition Terms
GRUSF sits 75% above its 52-week low of $0.269 on light trading volume (0.1× avg).
Summary
Grown Rogue closed initial transactions to enter New York through a planned acquisition of PharmaCann's New York assets, backed by $15 million in project-based financing from a capital partner.
Key Events · M&A and Partnerships · GRUSF
-
New York Entry via 51/49 JV
Grown Rogue formed Grown Rogue New York LLC (GRNY) with a capital partner, retaining 51% ownership, to acquire PharmaCann's New York license and assets including four Verilife dispensaries and the Hamptonburgh cultivation facility.
-
$15M Project Financing Secured
Capital partner invested $10M for 49% preferred equity in GRNY and committed an additional $5M drawable term loan at 15% interest. Preferred equity converts at $0.55/$0.65/$0.76 into ~18.2M SVS (~7% dilution if converted today).
-
Up to $9M Secured Loan to PCNY
GRNY will provide up to $9M in secured funding to PharmaCann's New York entity to ramp production at Hamptonburgh, fund capital expenditures, and cover working capital during the transition.
-
Anticipated $4.5M Purchase Price
The planned acquisition price is approximately $4.5M, with $3M payable upon regulatory approval of the change of control. Definitive purchase agreements expected within four weeks.
Analysis · GRUSF · Industrial Applications And Services
Grown Rogue has formalized its entry into New York's cannabis market through a 51/49 joint venture with a capital partner, securing $15 million in project-based financing to acquire PharmaCann's New York license and assets. The deal includes a $10 million preferred equity investment convertible into approximately 18.2 million shares (about 7% dilution at current prices), a $5 million drawable term loan, and up to $9 million in secured funding to ramp production at the Hamptonburgh facility. Management projects the New York operations will become cash flow positive within nine months and generate roughly $600,000 in monthly after-tax cash flow within 18 months, supported by an anticipated $20 million in annual cost reductions. The transaction is subject to execution of definitive purchase agreements (expected within four weeks) and regulatory approval of the change of control.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 37.4% of the 3413 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GRUSF was trading at $0.47 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $117.5M. The 52-week trading range was $0.27 to $0.52. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.